Dermatologic DiseaseNCT04495036
Acceptance of Telemedicine in Dermatology Patients, Physicians and Medical Staff
An observational study of Dermatologic Disease, run by University Hospital, Basel, Switzerland at 3 sites in Switzerland.
Trial summary
This study is to investigate the current use and intention to use of teledermatology in Swiss dermatology patients, dermatologists, other physicians and medical staff. Read more about this study
- Who is it for?
- Ages 18 years and olderHealthy volunteers can take part
- Conditions the study is for
- Dermatologic Disease
- What is being tested?
- data collection (21-items-patient descriptive survey) and data collection (23-items-physician descriptive survey)
- How many people
- 683 participants
- Where
- 3 sitesSwitzerland
- Study dates
- 1 Jul 2019to 31 Jan 2020
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Study population: Patients treated in the Department of Dermatology of the Cantonal Hospital Aarau and the University Hospitals Basel and Zürich and Dermatologists, other physicians and medical staff of the Department of Dermatology of the Cantonal Hospital Aarau and the University Hospitals Basel and Zürich.
Who may be able to join
- patients treated in the Department of Dermatology of the Cantonal Hospital Aarau and the University Hospitals Basel and Zürich
- dermatologists, other physicians and medical staff of the Department of Dermatology of the Cantonal Hospital Aarau and the University Hospitals Basel and Zürich
Who cannot join
- -
Trial locations and contacts
3 sites in 1 country.
Switzerland3 sites
Kantonsspital Aarau
Aarau, 5001
Department of Dermatology, University Hospital Basel
Basel, 4031
University Hospital Zürich
Zurich, 8091
About this study
This study is to investigate the current use and intention to use of teledermatology in Swiss dermatology patients, dermatologists, other physicians and medical staff.
Read the detailed description
Telemedicine, the use of telecommunication and information technology to provide clinical health care from a distance, has become an increasing role in basic medical care internationally. Telemedicine is particularly suitable for skin diseases. In order to improve the use of evidence-based telemedicine, the Swiss patients' preferences regarding teledermatology versus face-to-face consultations and the patients' and physicians' determinants of acceptance for teledermatology are investigated in this study. Dermatology patients are asked to complete a newly-created 21-items-survey; Swiss dermatologists, other physicians and medical staff on telemedicine will complete a similar newly-created, 23-items-questionnaire. A descriptive statistical analysis (e.g. gender, age, place of residence (city or country), waiting time) will be performed.
- Conditions
- Dermatologic Disease
- Being tested
- data collection (21-items-patient descriptive survey), data collection (23-items-physician descriptive survey)
- Keywords
- Teledermatology, Telemedicine
- Medical subject headings
- Skin Diseases
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
data collection (21-items-patient descriptive survey)Other
Dermatology patients are asked to complete a 21-items-survey while waiting for the doctor's consultation. Following variables will be addressed:
- Demographic data of telemedicine users and non-users
- Subjective disease perception of the dermatology patients
- Use of internet, telemedicine and telemedicine insurance model
- Patients´ willingness for additional features of telemedicine
- Advantages and disadvantages telemedicine and face-to-face consultation
- Suitable fields of dermatology for telemedicine from the patient's perspective
- Recommended structure of telemedical services by users and non-users
data collection (23-items-physician descriptive survey)Other
To obtain the view of Swiss dermatologists, other physicians and medical staff on telemedicine a 23-items-survey will be completed. Following variables will be addressed:
- Objective disease perception of the treating dermatologist (regarding the urgency of the patient's medical examination, the functional impairment and cosmetic burden due to patient's disease, the impairment of life quality due to patient's disease and the estimation of the course of the patient's disease)
- Suitable fields of dermatology for telemedicine from the physician's and medical staff's perspective
| Study group | Role | What they receive |
|---|---|---|
| dermatology patients | Not described Receives: Other: data collection (21-items-patient descriptive survey) | |
| physicians and medical staff | Not described Receives: Other: data collection (23-items-physician descriptive survey) |
What is being measured
The primary outcome is the main question the study is designed to answer.
descriptive analysis: deviation in influencing factors for the acceptance of teledermatology
Assessment of the deviation in influencing factors for the acceptance of teledermatology (subjective disease perception versus objective assessment by physicians)
Measured: at baseline
descriptive analysis of the impact of medical education for the acceptance of telemedicine among dermatologists vs. other physicians vs. medical staff vs. patients
Comparison of the impact of medical education for the acceptance of telemedicine among dermatologists vs. other physicians vs. medical staff vs. patients
Measured: at baseline
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted31 Jul 2020
- Study start1 Jul 2019
- Primary completion31 Jan 2020
- Study completion31 Jan 2020
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for Dermatologic DiseaseStudies of the same condition, open and under way.
- More trials run by University Hospital, Basel, SwitzerlandThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 683 participants (actual)
Sponsor and investigators
- Lead sponsor
- University Hospital, Basel, Switzerland
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- Lara Valeska Maul, Dr. med., Principal investigator, Department of Dermatology, University Hospital Basel
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT04495036
- Sponsor's protocol ID
- Req-2019-00523; sp20Maul2
- Status last verified
- Aug 2020
- First submitted
- 28 Jul 2020
- Last updated
- 4 Aug 2020
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Publications
Maul LV, Jahn AS, Pamplona GSP, Streit M, Gantenbein L, Muller S, Nielsen ML, Greis C, Navarini AA, Maul JT. Acceptance of Telemedicine Compared to In-Person Consultation From the Providers' and Users' Perspectives: Multicenter, Cross-Sectional Study in Dermatology. JMIR Dermatol. 2023 Aug 11;6:e45384. doi: 10.2196/45384.
PubMed 37582265
Study at a glance
From the registry record, last updated by the sponsor on 4 Aug 2020. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Acceptance of Telemedicine in Dermatology Patients, Physicians and Medical Staff
- ClinicalTrials.gov ID
- NCT04495036
- Acronym / sponsor ID
- Req-2019-00523; sp20Maul2
- Conditions
- Dermatologic Disease
- Keywords
- Teledermatology, Telemedicine
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 683 participants (actual)
- Lead sponsor
- University Hospital, Basel, SwitzerlandUniversity, hospital or other
- Study start
- 1 Jul 2019 (actual)
- Primary completion
- 31 Jan 2020 (actual)
- Study completion
- 31 Jan 2020 (actual)
- First posted
- 31 Jul 2020 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This study is to investigate the current use and intention to use of teledermatology in Swiss dermatology patients, dermatologists, other physicians and medical staff.
Detailed description
Telemedicine, the use of telecommunication and information technology to provide clinical health care from a distance, has become an increasing role in basic medical care internationally. Telemedicine is particularly suitable for skin diseases. In order to improve the use of evidence-based telemedicine, the Swiss patients' preferences regarding teledermatology versus face-to-face consultations and the patients' and physicians' determinants of acceptance for teledermatology are investigated in this study. Dermatology patients are asked to complete a newly-created 21-items-survey; Swiss dermatologists, other physicians and medical staff on telemedicine will complete a similar newly-created, 23-items-questionnaire. A descriptive statistical analysis (e.g. gender, age, place of residence (city or country), waiting time) will be performed.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| dermatology patients | – | Other: data collection (21-items-patient descriptive survey) |
| physicians and medical staff | – | Other: data collection (23-items-physician descriptive survey) |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
- Study population
- Patients treated in the Department of Dermatology of the Cantonal Hospital Aarau and the University Hospitals Basel and Zürich and Dermatologists, other physicians and medical staff of the Department of Dermatology of the Cantonal Hospital Aarau and the University Hospitals Basel and Zürich.
Key inclusion criteria (2 listed)
- patients treated in the Department of Dermatology of the Cantonal Hospital Aarau and the University Hospitals Basel and Zürich
- dermatologists, other physicians and medical staff of the Department of Dermatology of the Cantonal Hospital Aarau and the University Hospitals Basel and Zürich
Key exclusion criteria (1 listed)
- -
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| data collection (21-items-patient descriptive survey)Dermatology patients are asked to complete a 21-items-survey while waiting for the doctor's consultation. Following variables will be addressed: * Demographic data of telemedicine users and non-users * Subjective disease perception of the dermatology patients * Use of internet, telemedicine and telemedicine insurance model * Patients´ willingness for additional features of telemedicine * Advantages and disadvantages telemedicine and face-to-face consultation * Suitable fields of dermatology for telemedicine from the patient's perspective * Recommended structure of telemedical services by users and non-users | Other | dermatology patients |
| data collection (23-items-physician descriptive survey)To obtain the view of Swiss dermatologists, other physicians and medical staff on telemedicine a 23-items-survey will be completed. Following variables will be addressed: * Objective disease perception of the treating dermatologist (regarding the urgency of the patient's medical examination, the functional impairment and cosmetic burden due to patient's disease, the impairment of life quality due to patient's disease and the estimation of the course of the patient's disease) * Suitable fields of dermatology for telemedicine from the physician's and medical staff's perspective | Other | physicians and medical staff |
Primary outcome
descriptive analysis: deviation in influencing factors for the acceptance of teledermatology
Time frame: at baseline
Assessment of the deviation in influencing factors for the acceptance of teledermatology (subjective disease perception versus objective assessment by physicians)
descriptive analysis of the impact of medical education for the acceptance of telemedicine among dermatologists vs. other physicians vs. medical staff vs. patients
Time frame: at baseline
Comparison of the impact of medical education for the acceptance of telemedicine among dermatologists vs. other physicians vs. medical staff vs. patients
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 4 Aug 2020.
- Derived from this study: PubMed 37582265Maul LV, Jahn AS, Pamplona GSP, Streit M, Gantenbein L, Muller S, Nielsen ML, Greis C, Navarini AA, Maul JT. Acceptance of Telemedicine Compared to In-Person Consultation From the Providers' and Users' Perspectives: Multicenter, Cross-Sectional Study in Dermatology. JMIR Dermatol. 2023 Aug 11;6:e45384. doi: 10.2196/45384.
Related trials for Dermatologic Disease
Not yet recruitingPhase 2
Extension Study of Safety and Tolerability of DDY391 in Participants With Moderate to Severe Psoriatic Arthritis (CDDY391A12201-extension)
Moderate to Severe Psoriatic Arthritis
RecruitingPhase 1/2
Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)
Solid Tumor, Non-Small Cell Lung Cancer
RecruitingPhase 1
IL-17 Blockade to Decrease irAEs (REPLAY)
Metastatic Melanoma
Active, not recruiting
Streamlined Geriatric and Oncological Evaluation Based On IC Technology
Breast Cancer, Comorbidities and Coexisting Conditions
RecruitingPhase 2
Gene Signatures to Guide HR+MBC Therapy in a Diverse Cohort
Invasive Mammary Carcinoma, Metastatic Breast Cancer
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Lara Valeska Maul, Dr. med. principal investigator
Department of Dermatology, University Hospital Basel
3 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Dermatologic Disease, run by University Hospital, Basel, Switzerland at 3 sites in Switzerland.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 2 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 4 Aug 2020. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 3 sites in Switzerland. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
descriptive analysis: deviation in influencing factors for the acceptance of teledermatology (time frame: at baseline). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT04495036, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 4 Aug 2020.